Zhejiang NHU Company (002001) Q2 2025 earnings summary

Executive summary

• Achieved operating revenue of ¥11.10 billion, up 12.76% year-over-year, and net profit attributable to shareholders of ¥3.60 billion, up 63.46% year-over-year.

• Focused on global market expansion, innovation, and risk management, with steady progress in project construction and R&D initiatives.

• Implemented a 'Quality and Returns Dual Improvement' action plan, including share repurchase and special dividend distribution.

Financial highlights

• Operating revenue: ¥11.10 billion (up 12.76% YoY); net profit: ¥3.60 billion (up 63.46% YoY).

• Gross margin for pharmaceutical chemicals rose by 9.27 percentage points YoY to 47.41%.

• Basic and diluted EPS: ¥1.17 (up 64.79% YoY); weighted average ROE: 11.87% (up 3.29 pts YoY).

• Net cash flows from operating activities: ¥3.24 billion (up 51.65% YoY).

• Total assets: ¥43.73 billion; net assets: ¥30.49 billion as of June 30, 2025.

Outlook and guidance

• Continued focus on technological development, product innovation, and global expansion to drive sustainable growth.

• Ongoing implementation of market value management and investor confidence initiatives.